HOOKIPA Pharma Inc.: A Leader in Immunotherapeutics against Infectious Diseases and Cancers New York-based clinical stage biopharmaceutical company, HOOKIPA Pharma Inc., is riding high on the success of its proprietary arenavirus platform. The company specializes in developing cutting-edge immunotherapeutics that target infectious diseases and cancers. With a strong focus on research and development, HOOKIPA Pharma Inc. is on a mission to revolutionize healthcare solutions for millions of patients worldwide. The company's lead infectious disease product candidate is HB-101, which is undergoing a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. HOOKIPA's lead oncology product candidates, HB-201 and HB-202, are also making waves with a Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. In a significant development, HOOKIPA recently collaborated with Gilead Sciences, Inc. to explore potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. This partnership holds immense promise for HOOKIPA as it expands its research and development initiatives. HOOKIPA Pharma Inc. was incorporated in 2011 and has become a powerhouse in the biopharmaceutical industry with its innovative approach to healthcare solutions, solidifying its position as a leader in the field.
HOOKIPA Pharma's ticker is HOOK
The company's shares trade on the NASDAQ stock exchange
They are based in Vienna, Austria
There are 51-200 employees working at HOOKIPA Pharma
It is hookipapharma.com
HOOKIPA Pharma is in the Healthcare sector
HOOKIPA Pharma is in the Biotechnology industry
The following five companies are HOOKIPA Pharma's industry peers: